Among the many hazards of uncontrolled type 2 diabetes mellitus (T2DM) are serious cardiovascular (CV) and renal complications. Fortunately, today’s clinician has an expanding arsenal of weapons to stave off these comorbidities, while at the same time ensuring adequate glycemic control. One of the most recent additions are the oral sodium-glucose cotransporter 2 (SGLT2) inhibitors, whose unique mechanism of action is complementary to other agents that address T2DM. In this case-based activity for NPs and PAs, Dr Anne Peters reviews how the SGLT2 inhibitors work and discusses their clinical benefits such as weight control and CV and renoprotective properties. A real-world patient simulation illuminates strategies for patient selection, patient education, counseling, and improving adherence to therapy.
Interactive, audio-enhanced slide lecture
After completing this activity, participants should be better able to:
- Integrate SGLT2 inhibitors into care of patients with T2DM based on patient-specific factors, including CV risk and renal status
- Describe the CV benefits of SGLT2 inhibitors as demonstrated in randomized clinical trials
- Implement the latest national guidelines/recommendations and evidence-based strategies in patient-centered care for T2DM
NPs and PAs
There are no prerequisites to participate in this activity.
Continuing Nursing Education Provider Unit, Boston University School of Medicine is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.
This educational activity has been provided by Continuing Nursing Education Provider Unit, Boston University School of Medicine and jointly provided by Practicing Clinicians Exchange.
Contact hours: 1.0, which are eligible for 1.0 pharmacology credits.
Course director: Jason Worcester, MD, Boston University School of Medicine
CNE course advisor: Claire Murphy, MSN, NP-C, Boston University School of Medicine
This activity has been reviewed by the AAPA Review Panel and is compliant with AAPA CME Criteria. This activity is designated for 1.00 AAPA Category 1 CME credits. Approval is valid for one year from 10/31/2018. PAs should only claim credit commensurate with the extent of their participation.
This program was cosupported by educational grants from Amgen; Astellas; Boehringer Ingelheim Pharmaceuticals, Inc. and Lilly USA, LLC; Genentech; Gilead Sciences, Inc.; Neurocrine Biosciences and Teva Pharmaceuticals; Sanofi US; Shire; and Sunovion Pharmaceuticals, Inc.
This activity is supported by an educational grant from Boehringer Ingelheim Pharmaceuticals, Inc. and Lilly USA, LLC.
The opinions or views expressed in this continuing education activity are those of the faculty and do not necessarily reflect the opinions or recommendations of the American Academy of Physician Assistants, Boston University School of Medicine, Continuing Education Alliance, Practicing Clinicians Exchange, or any educational supporter.
THIS CONTINUING MEDICAL EDUCATION PROGRAM IS INTENDED SOLELY FOR EDUCATIONAL PURPOSES FOR QUALIFIED HEALTHCARE PROFESSIONALS. IN NO EVENT SHALL BOSTON UNIVERSITY BE LIABLE FOR ANY DECISION MADE OR ACTION TAKEN IN RELIANCE ON THE INFORMATION CONTAINED IN THE PROGRAM. IN NO EVENT SHOULD THE INFORMATION CONTAINED IN THE PROGRAM BE USED AS A SUBSTITUTE FOR PROFESSIONAL CARE. NO PHYSICIAN-PATIENT RELATIONSHIP IS BEING ESTABLISHED.
Boston University School of Medicine asks all individuals involved in the development and presentation of Continuing Medical Education (CME) activities to disclose all relevant relationships with commercial interests. This information is disclosed to CME activity participants. Boston University School of Medicine has procedures to resolve any apparent conflicts of interest. In addition, faculty members are asked to disclose when any discussion of unapproved use of pharmaceuticals and devices is being discussed.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration.
Dr Peters: advisory board: Abbott, Becton Dickinson, Boehringer Ingelheim, Lexicon, Lilly, Livongo, Medscape, Merck, Novo Nordisk, OptumHealth, Sanofi, Science 37; grant/research support: AstraZeneca, Dexcom, MannKind; speakers bureau: Novo Nordisk.
The Planning Committee for this activity included Claire Murphy, MSN, NP-C, Carmela A. Townsend, DNP, MS/MBA, RN, Jody Walker, MS, Julie L. White, MS, and Jason Worcester, MD, of Boston University School of Medicine; Mark Christiansen, PhD, PA-C, of the University of the Pacific; and Ruth Cohen, Warren Beckman, and Margaret Inman of Practicing Clinicians Exchange. None of the aforementioned members of the Planning Committee have any relevant relationships to disclose.
Participants wishing to earn CE/CME credit must:
- Read the content
- Relate the content material to the learning objectives
- Complete the post-test and evaluation form online
Successful completion of the post-test is required to earn CE/CME credit. Successful completion is defined as a cumulative score of at least 70%.
The estimated time to complete each activity is 1 hour.
Release date: October 31, 2018
Expiration date: October 30, 2019
Internet Explorer 8.0+ for Windows 2000, 2003, XP, Vista, or Windows 7, 8, or 10
Google Chrome 18.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 13.0+ for Windows, Mac OS, or Linux
Safari 4.0+ for Mac OSX 10.5+
© 2018 Practicing Clinicians Exchange. All Rights Reserved. CPCE93218-7H